- Home
- DPG vs STTK Comparison
DPG vs STTK Comparison
Compare DPG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DPG | STTK |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.2M | 538.3M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DPG | STTK |
|---|---|---|
| Price | $14.68 | $6.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 69.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.13 | $0.71 |
| 52 Week High | $15.15 | $8.33 |
Technical Indicators
Market Signals| Indicator | DPG | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 59.40 |
| Support Level | $14.06 | $5.81 |
| Resistance Level | $14.71 | $6.81 |
| Average True Range (ATR) | 0.25 | 0.59 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 99.98 | 87.28 |
Price Performance
Historical ComparisonAbout DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.